Emerging Infectious Disease ISSN: 1080-6059

Characterization of Flagella Produced by Clinical Strains of Stenotrophomonas maltophilia

Doroti de Oliveira-Garcia*†, Monique Dall'Agnol‡, Mónica Rosales‡, Ana C.G.S. Azzuz§, Marina B. Martinez†§, and Jorge A. Girón‡

Author affiliations: *Laboratório Clínico do Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; †Departamento de Microbiologia do Instituto de Ciências Biomédicas da Universidade de São Paulo, São Paulo, Brazil; ‡Benemerita Universidad Autónoma de Puebla, Puebla, México; §Departamento de Análises Clínicas da Faculdade de Ciências Farmacêuticas da Universidade de São Paulo, São Paulo, Brazil;

Main Article

Figure 2

Analysis of flagella purified from SMDP92. (A) sodium dodecyl-sulfate polyacrylamide gel electrophoresis of purified flagella, showing the 38-kDa flagellin subunit. Lane 1, molecular weight standards; lane 2, purified SMFliC. (B) Immunoblotting and reactivity of purified flagella with anti-SMFliC antibodies. The 38-kDa flagellin is indicated by an arrow. (C) Electron microscopy of purified flagella visualized by negative staining. Bar, 0.37 μm.

Figure 2. Analysis of flagella purified from SMDP92. (A) sodium dodecyl-sulfate polyacrylamide gel electrophoresis of purified flagella, showing the 38-kDa flagellin subunit. Lane 1, molecular weight standards; lane 2, purified SM_FliC. (B) Immunoblotting and reactivity of purified flagella with anti-SM_FliC antibodies. The 38-kDa flagellin is indicated by an arrow. (C) Electron microscopy of purified flagella visualized by negative staining. Bar, 0.37 μm.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.